Q4 2025 · 13F-HR
Foresite Capital Management VI LLCholdings as filed
Filed 2026-02-17 · accession 0001104659-26-015412
$330.8M
Reported value
12
Positions
2025-12-31
Period end
The Brief · Foresite Capital Management VI LLC · Q4 2025
AI · grounded in 13F
Foresite Capital Management VI LLC established a new position in NTRA worth $15.4M. The fund also opened new stakes in AGIO for $14.4M and ATAI for $11.2M. On the sell side, the fund closed its position in AKRO, reducing exposure by $11.6M. Other activity included increasing shares of VSTM by 19.8% and trimming CRVS by 20.2%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 156944100 | CGON | CG Oncology, Inc. | $92.2M | 27.9% | 2,221,474 | Common | SOLE |
| 75382E208 | RAPT | RAPT Therapeutics, Inc. | $52.9M | 16.0% | 1,562,500 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC. | $41.5M | 12.5% | 4,247,670 | Common | SOLE |
| 152309100 | CNTA | Centessa Pharmaceuticals plc | $34.1M | 10.3% | 1,364,019 | Common | SOLE |
| 92337C203 | VSTM | Verastem, Inc. | $24.2M | 7.32% | 3,135,120 | Common | SOLE |
| 24823R105 | DNLI | Denali Therapeutics Inc. | $16.5M | 4.99% | 1,000,000 | Common | SOLE |
| 632307104 | NTRA | Natera, Inc. | $15.4M | 4.66% | 67,356 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS, INC. | $14.4M | 4.36% | 530,000 | Common | SOLE |
| 501575104 | KYMR | Kymera Therapeutics, Inc. | $11.4M | 3.44% | 146,332 | Common | SOLE |
| N0731H103 | ATAI | Atai Beckley N.V. | $11.2M | 3.40% | 2,750,000 | Common | SOLE |
| 221015100 | CRVS | Corvus Pharmaceuticals, Inc. | $10.6M | 3.21% | 1,381,233 | Common | SOLE |
| 433313103 | HNGE | Hinge Health, Inc. | $6.3M | 1.90% | 135,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.